BCL2 and acute myeloid leukemia: Additionally, targeting XIAP together with BCL‐2 was recently suggested as promising treatment for aggressive AML subtypes, where certain mutations, karyotypes and TP53 transcriptional activity correlated with response (Hashimoto et al, 2021).